Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPME1 | Q9Y570 | 12/20 | 1.00 |
| ▸ | APEH | P13798 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16194669 | 1.00 | PPME1 (1.00) | PPME1APEHPKML3MBTL1MAPT | |
| SCHEMBL16194668 | 1.00 | PPME1 (1.00) | PPME1APEHPKML3MBTL1MAPT | |
| SCHEMBL29289250 | 0.72 | ALDH1A1 (0.60) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL29289251 | 0.72 | ALDH1A1 (0.60) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL11565020 | 0.69 | CYP1A2 (0.65) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL8425618 | 0.67 | PKM (0.51) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL8425615 | 0.67 | PKM (0.51) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL8425622 | 0.67 | PKM (0.51) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL29289213 | 0.66 | MAPT (0.55) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL29289216 | 0.66 | MAPT (0.55) | PPME1PKML3MBTL1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190592-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | Medical Diagnostic Laboratories, L.L.C. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10167472-B2 | PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170226520-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | Medical Diagnostic Laboratories, L.L.C. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9663789-B2 | PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9657349-B2 | PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150284723-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE ENDOMETRIAL AND BREAST CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140323546-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2014-10-30 | — | — | US | disclosed |